布地格福配合呼吸康复疗法对COPD稳定期患者肺功能及病情的改善效果

Improvement effect of budesonide and formoterol fumarate powder combined with respiratory rehabilitation therapy on pulmonary function and disease condition in patients with stable chronic obstructive pulmonary disease

目的观察布地格福配合呼吸康复疗法对慢性阻塞性肺疾病(COPD)稳定期患者肺功能及病情的改善效果。方法按照随机投掷法将2022年11月—2023年10月晋江市医院(上海市第六人民医院福建医院)收治的COPD稳定期患者52例进行分组,分为布地格福配合组(26例,采用布地格福配合呼吸康复疗法)和布地奈德配合组(26例,采用布地奈德配合呼吸康复疗法)。2组均持续干预4周。比较2组干预前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、最大自主通气量(MVV)及呼气流量峰值(PEF)]、血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))、动脉血氧饱和度(SaO_(2))]、病情控制情况[中文版慢性阻塞性肺疾病评估测试(CAT)评分]、生活质量[圣乔治医院呼吸问题调查问卷(SGRQ)评分],用药安全性。结果干预4周后,2组FVC、FEV_(1)、MVV及PEF升高,且布地格福配合组高于布地奈德配合组(P<0.01);2组血气分析指标较干预前改善,且布地格福配合组PaO_(2)、SaO_(2)高于布地奈德配合组,PaCO_(2)低于布地奈德配合组(P<0.05或P<0.01);2组CAT评分与SGRQ评分较干预前下降,且布地格福配合组各项评分低于布地奈德配合组(P<0.05或P<0.01)。布地格福配合组与布地奈德配合组不良反应总发生率比较,差异无统计学意义(7.69%vs.19.23%,χ^(2)=0.660,P=0.416)。结论对于COPD稳定期患者采用布地格福配合呼吸康复疗法进行干预,不仅能有效提升患者肺功能,改善血气分析,还能加强对病情的控制,降低对其日常生活的影响,也可在一定程度上保障用药安全性。

Objective To observe the improvement effect of budesonide and formoterol fumarate powder combined with respiratory rehabilitation therapy on pulmonary function and disease condition in patients with stable COPD.Methods A total of 52 patients with stable COPD admitted to Jinjiang Hospital/Fujian Hospital of Shanghai Sixth People′s Hospital from November 2022 to October 2023 were randomly divided into the BGF combination group with 26 cases who were treated with budesonide and formoterol fumarate powder combined with respiratory rehabilitation therapy and the budesonide combination group with 26 cases who were treated with budesonide combined with respiratory rehabilitation therapy according to the random toss method.Both groups were received continuous intervention for 4 weeks.Pulmonary function indicators(FVC,FEV_(1),MVV,PEF),blood gas analysis indicators(PaO_(2),PaCO_(2),SaO_(2)),CAT score,SGRQ score before and after intervention,and medication safety were compared between the two groups.Results After 4 weeks of intervention,FVC,FEV_(1),MVV,and PEF increased in the two groups,and the BGF combination group had higher values than those in the budesonide combination group(P<0.01).The blood gas analysis indicators improved in the two groups compared with those before intervention,and the BGF combination group had higher PaO_(2),SaO_(2) and lower PaCO_(2) than those in the budesonide combination group(P<0.05 or P<0.01).The CAT score and SGRQ score decreased in the two groups compared with those before intervention,and the BGF combination group had lower scores than those in the budesonide combination group(P<0.05 or P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the BGF combination group and the budesonide combination group(7.69%vs.19.23%,χ^(2)=0.660,P=0.416).Conclusion For patients with stable COPD,intervention with budesonide and formoterol fumarate powder and respiratory rehabilitation therapy can not only effectively improve pulmonary function and blood gas analysis,but also strengthen disease control,reduce the impact on daily life,and ensure medication safety to a certain extent.